These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21351583)

  • 1. [Recent advances in the study of new antifungal lead compounds].
    Wang SZ; Sheng CQ; Zhang WN
    Yao Xue Xue Bao; 2010 Aug; 45(8):966-75. PubMed ID: 21351583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent advances in the study of antifungal lead compounds with new chemical scaffolds].
    Shao LC; Sheng CQ; Zhang WN
    Yao Xue Xue Bao; 2007 Nov; 42(11):1129-36. PubMed ID: 18300466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
    Xie F; Ni T; Zhao J; Pang L; Li R; Cai Z; Ding Z; Wang T; Yu S; Jin Y; Zhang D; Jiang Y
    Bioorg Med Chem Lett; 2017 May; 27(10):2171-2173. PubMed ID: 28372907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazonium sulfate (Cresemba)--a new antifungal.
    Med Lett Drugs Ther; 2016 Mar; 58(1490):37-8. PubMed ID: 26963156
    [No Abstract]   [Full Text] [Related]  

  • 5. Design and synthesis of antifungal benzoheterocyclic derivatives by scaffold hopping.
    Sheng C; Che X; Wang W; Wang S; Cao Y; Yao J; Miao Z; Zhang W
    Eur J Med Chem; 2011 May; 46(5):1706-12. PubMed ID: 21411192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.
    Pasqualotto AC; Thiele KO; Goldani LZ
    Curr Opin Investig Drugs; 2010 Feb; 11(2):165-74. PubMed ID: 20112166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives.
    Dou D; Alex D; Du B; Tiew KC; Aravapalli S; Mandadapu SR; Calderone R; Groutas WC
    Bioorg Med Chem; 2011 Oct; 19(19):5782-7. PubMed ID: 21903403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [NEW ANTIFUNGAL DRUGS FOR PREVENTION AND TREATMENT OF VISCERAL MYCOSES].
    Pilmis B; Lortholary O; Lanternier FL
    Rev Prat; 2015 Dec; 65(10):1334-9. PubMed ID: 26979038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
    Seyedmousavi S; Verweij PE; Mouton JW
    Expert Rev Anti Infect Ther; 2015 Jan; 13(1):9-27. PubMed ID: 25488140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antifungal resistance in opportunistic pathogenic fungi (II). Imidazoles and triazoles].
    Martínez-Suárez JV; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 1996 Oct; 14(8):490-8. PubMed ID: 9011208
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery of highly potent triazole antifungal derivatives by heterocycle-benzene bioisosteric replacement.
    Jiang Z; Wang Y; Wang W; Wang S; Xu B; Fan G; Dong G; Liu Y; Yao J; Miao Z; Zhang W; Sheng C
    Eur J Med Chem; 2013 Jun; 64():16-22. PubMed ID: 23643831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
    Khidre RE; Abu-Hashem AA; El-Shazly M
    Eur J Med Chem; 2011 Oct; 46(10):5057-64. PubMed ID: 21890245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazonium sulfate for the treatment of fungal infection.
    Walker RC; Zeuli JD; Temesgen Z
    Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of antifungal evaluation of 2H-[1,2,3]Triazolo[4,5-g]isoquinoline-4,9-diones.
    Ryu CK; Oh SY; Choi SJ; Kang DY
    Chem Pharm Bull (Tokyo); 2014; 62(11):1119-24. PubMed ID: 25196129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targets and delivery systems for antifungal therapy.
    Walsh TJ; Viviani MA; Arathoon E; Chiou C; Ghannoum M; Groll AH; Odds FC
    Med Mycol; 2000; 38 Suppl 1():335-47. PubMed ID: 11204162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, Characterization and Antimicrobial Evaluation of Some Heterocyclic Condensed Systems with Bridgehead Nitrogen from Thiazolotriazole Class.
    Barbuceanu SF; Draghici C; Barbuceanu F; Bancescu G; Saramet G
    Chem Pharm Bull (Tokyo); 2015; 63(9):694-700. PubMed ID: 26329862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of some new thiazolo[3,2-a]pyridines and related heterocyclic systems.
    al-Thebeiti MS
    Farmaco; 2000 Feb; 55(2):109-18. PubMed ID: 10782381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
    Guinea J; Bouza E
    Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.